are viewed in confidence by a data monitoring committee), and it is possible for a member of the statistical team to remain blinded so that they can continue to update the SAP without knowledge of the unblinded trial results.

We agree that sufficient justification should be provided for the choice of a noninferiority margin, but this information is crucial to the planning of the study and should therefore be provided in the protocol, together with the clinical rationale and not just the statistical justification of the margin.

Carrol Gamble, PhD
Steff Lewis, PhD
Stephen Senn, PhD

Author Affiliations: Biostatistics Department, University of Liverpool, Liverpool, England (Gamble); Edinburgh University, Edinburgh, Scotland (Lewis); Luxembourg Institute of Health, Strassen, Luxembourg (Senn).

Corresponding Author: Carrol Gamble, PhD, Biostatistics Department, University of Liverpool, Block F Waterhouse Bldg, 1-5 Brownlow St, Liverpool L69 3GL, England (c.gamble@liverpool.ac.uk).

Conflict of Interest Disclosures: The authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and none were reported.


CORRECTION

Error in a Figure: In the Original Investigation entitled “Association of Inhaled Corticosteroids and Long-Acting Muscarinic Antagonists With Asthma Control in Patients With Uncontrolled, Persistent Asthma: A Systematic Review and Meta-analysis,” published in the April 10, 2018, issue of JAMA, there was an error in Figure 3A. In the forest plot, the headings of “Favors LAMA” and “Favors Control” should be switched. This article was corrected online.

Guidelines for Letters

Letters discussing a recent JAMA article should be submitted within 4 weeks of the article's publication in print. Letters received after 4 weeks will rarely be considered. Letters should not exceed 400 words of text and 5 references and may have no more than 3 authors. Letters reporting original research should not exceed 600 words of text and 6 references and may have no more than 7 authors. They may include up to 2 tables or figures but online supplementary material is not allowed. All letters should include a word count. Letters must not duplicate other material published or submitted for publication. Letters not meeting these specifications are generally not considered. Letters being considered for publication ordinarily will be sent to the authors of the JAMA article, who will be given the opportunity to reply. Letters will be published at the discretion of the editors and are subject to abridgement and editing. Further instructions can be found at http://jamanetwork.com/journals/jama/pages/instructions-for-authors. A signed statement for authorship criteria and responsibility, financial disclosure, copyright transfer, and acknowledgment and the ICMJE Form for Disclosure of Potential Conflicts of Interest are required before publication. Letters should be submitted via the JAMA online submission and review system at https://manuscripts.jama.com. For technical assistance, please contact jama-letters@jamanetwork.org.

Section Editor: Jody W. Zylke, MD, Deputy Editor.